The Future of Pharmaceutical Manufacturing in Africa
Why local drug production has become a continental strategic priority.
Why Is Demand Increasing?
Africa currently imports the large majority of its pharmaceuticals, a vulnerability that the COVID-19 pandemic exposed sharply when global supply chains broke down. Governments and regional bodies such as the African Union have since made local pharmaceutical manufacturing a strategic priority, backed by procurement policies favouring locally produced medicines.
Who Is Buying?
Government health ministries and public procurement programmes are the largest buyers, alongside regional distributors supplying private pharmacies and hospitals. International donor-funded health programmes are also increasingly required to source a share of medicines locally where quality standards allow.
Which Countries Have an Advantage?
South Africa, Egypt and Morocco have the continent's most established pharmaceutical manufacturing bases, with existing regulatory approval systems recognised internationally. Kenya, Nigeria and Rwanda are investing heavily in new manufacturing capacity, often with support from international development partners.
What Margins Are Possible?
Generic drug manufacturing carries moderate margins constrained by competitive tendering, particularly for government contracts, while specialised formulations and active pharmaceutical ingredient production, where local capacity is scarce, can command significantly higher margins.
What Certifications Are Needed?
Good Manufacturing Practice certification is mandatory, along with national medicines regulatory authority approval, and increasingly, prequalification from the World Health Organization for manufacturers seeking to supply donor-funded and cross-border programmes.
What Financing Exists?
Pharmaceutical manufacturing is a priority sector for several development finance institutions, including the IFC and Africa Finance Corporation, and blended finance structures combining donor and commercial capital are increasingly available given the sector's public health significance.
What Mistakes Do Beginners Make?
New entrants frequently underestimate the multi-year timeline and cost required to achieve Good Manufacturing Practice certification and regulatory approval, and enter the market without the working capital needed to survive that pre-revenue period.
Which Technologies Are Changing the Industry?
Modular, prefabricated cleanroom and production facilities are shortening the time and cost required to build a compliant manufacturing plant, and digital quality-management systems are making it easier for smaller manufacturers to meet international certification requirements.
Where Is the Greatest Profit in the Value Chain?
Active pharmaceutical ingredient production, which Africa currently imports almost entirely from India and China, carries the highest margins and strategic value of any stage in the pharmaceutical value chain, though it also requires the most capital and technical expertise.
How Can One Participate?
New entrants without deep pharmaceutical expertise are better served starting with contract manufacturing of established generic formulations under a technology transfer partnership with an experienced manufacturer, building regulatory track record before attempting more complex or higher-value production.